Plain-English translation of NCT06477536 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a follow-up study for people who already participated in an earlier trial testing , a new medication for generalized pustular psoriasis—a rare and serious form of psoriasis with widespread pus-filled bumps. All participants in this study will receive as an intravenous infusion (a shot into the vein) every four weeks, and researchers will continue to monitor how safe and effective the medication is over time.
Generalized pustular psoriasis is a severe condition that can be difficult to treat, and this trial aims to understand whether this medication can provide long-term relief and safety for people living with this challenging disease.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive an intravenous infusion of the medication every four weeks throughout the study. Researchers will monitor your safety and how well the treatment is working by conducting regular visits, blood tests, and assessments. The study will track how your body processes the medication and whether your body develops any immune response to it over time.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
China